PhaseBio’s Bentracimab Could Benefit From Growth In Brilinta Demand

 
• By Alaric DeArment
  
3-D Rendering Red Blood Cells
PhaseBio presented data at AHA on its Brilinta-reversing agent, bentracimab • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Blood and Clotting

More from Therapeutic Category